A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters
Copyright © 2020 Fagre, Manhard, Adams, Eckley, Zhan, Lewis, Rocha, Woods, Kuo, Liao, Li, Corper, Challa, Mount, Tumanut, Tjalkens, Aboellail, Fan and Schountz..
The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clinical management of COVID-19 are needed. We identified a panel of human monoclonal antibody clones from a yeast display library with specificity to the SARS-CoV-2 spike protein receptor binding domain that neutralized the virus in vitro. Administration of the lead antibody clone to Syrian hamsters challenged with SARS-CoV-2 significantly reduced viral load and histopathology score in the lungs. Moreover, the antibody interrupted monocyte infiltration into the lungs, which may have contributed to the reduction of disease severity by limiting immunopathological exacerbation. The use of this antibody could provide an important therapy for treatment of COVID-19 patients.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 11(2020) vom: 28., Seite 614256 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fagre, Anna C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.01.2021 Date Revised 10.11.2023 published: Electronic-eCollection UpdateOf: bioRxiv. 2020 Sep 28;:. - PMID 33024962 Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2020.614256 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319552837 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319552837 | ||
| 003 | DE-627 | ||
| 005 | 20231226202406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2020.614256 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319552837 | ||
| 035 | |a (NLM)33391285 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fagre, Anna C |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2021 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a UpdateOf: bioRxiv. 2020 Sep 28;:. - PMID 33024962 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Fagre, Manhard, Adams, Eckley, Zhan, Lewis, Rocha, Woods, Kuo, Liao, Li, Corper, Challa, Mount, Tumanut, Tjalkens, Aboellail, Fan and Schountz. | ||
| 520 | |a The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clinical management of COVID-19 are needed. We identified a panel of human monoclonal antibody clones from a yeast display library with specificity to the SARS-CoV-2 spike protein receptor binding domain that neutralized the virus in vitro. Administration of the lead antibody clone to Syrian hamsters challenged with SARS-CoV-2 significantly reduced viral load and histopathology score in the lungs. Moreover, the antibody interrupted monocyte infiltration into the lungs, which may have contributed to the reduction of disease severity by limiting immunopathological exacerbation. The use of this antibody could provide an important therapy for treatment of COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a monoclonal Ab | |
| 650 | 4 | |a therapeutic antibodies | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Manhard, John |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Eckley, Miles |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Shijun |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Juliette |e verfasserin |4 aut | |
| 700 | 1 | |a Rocha, Savannah M |e verfasserin |4 aut | |
| 700 | 1 | |a Woods, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Karina |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Wuxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Corper, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Challa, Dilip |e verfasserin |4 aut | |
| 700 | 1 | |a Mount, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Tumanut, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Tjalkens, Ronald B |e verfasserin |4 aut | |
| 700 | 1 | |a Aboellail, Tawfik |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Xiaomin |e verfasserin |4 aut | |
| 700 | 1 | |a Schountz, Tony |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 11(2020) vom: 28., Seite 614256 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g day:28 |g pages:614256 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2020.614256 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |b 28 |h 614256 | ||